BCRX Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
218.3M
+39.5%
156.4M
-61.5%
406.6M
+155.1%
159.4M
-2.4%
163.4M
Cost of Revenue
3.8M
-28.6%
5.4M
-43.5%
9.5M
+335.4%
2.2M
-21.8%
2.8M
Gross Profit
214.4M
+42.0%
151.0M
-62.0%
397.0M
+152.6%
157.2M
-2.1%
160.6M
Operating Expenses
115.9M
-86.4%
852.6M
+524.0%
136.6M
+7.1%
127.6M
-2.4%
130.8M
R&D
52.0M
-93.1%
758.1M
+1755.0%
40.9M
-8.4%
44.6M
+2.8%
43.4M
SG&A
64.0M
-32.3%
94.6M
-1.3%
95.8M
+15.4%
83.0M
-5.0%
87.4M
Operating Income
98.5M
+114.0%
-701598000
-369.4%
260.4M
+779.9%
29.6M
-0.7%
29.8M
EBITDA
98.4M
+114.0%
-700537000
-368.6%
260.8M
+771.4%
29.9M
-0.6%
30.1M
Net Income
78.4M
+110.9%
-721812000
-393.6%
245.8M
+1805.9%
12.9M
+153.7%
5.1M
EPS (Basic)
$0.31
+110.4%
$-2.98
-354.7%
$1.17
+1850.0%
$0.06
+200.0%
$0.02
EPS (Diluted)
$0.30
+110.1%
$-2.98
-366.1%
$1.12
+1766.7%
$0.06
+200.0%
$0.02
Shares (Diluted)
265.2M
+9.5%
242.3M
+10.5%
219.3M
-0.3%
219.9M
-0.0%
219.9M
BioCryst Pharmaceuticals (BCRX) โ€” Financials